๐๐จ๐ซ๐ญ๐ก ๐๐ฆ๐๐ซ๐ข๐๐ ๐๐๐ง๐๐๐ญ๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ข๐ณ๐, ๐๐ก๐๐ซ๐ & ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐๐ฉ๐จ๐ซ๐ญ (๐๐๐๐-๐๐๐๐)
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/dSg_gXik
The North America lancets market is set on an upward trajectory, with total revenues expected to grow from $710 Million in 2020 to an estimated $1,360 Million by 2035. This robust expansion is propelled by a surge in at-home testing, increasing prevalence of chronic illnesses such as diabetes, and innovation in minimally invasive lancet devices. Notable growth is observed in periods post-2025 due to accelerated adoption of advanced safety lancets and digital health integration. Hospitals and clinics remain major contributors, complemented by rapidly expanding sales through online channels. Year-over-year growth momentum is likely to be sustained by regulatory reforms, improved healthcare infrastructure, and ongoing product development.
Key Drivers
Rising Incidence of Diabetes: The growing number of diabetics in North America, with an estimated 37 million adults in the US alone, significantly pushes lancet demand for self-monitoring and professional diagnostics (Abbott Laboratories launched new lancet devices for continuous glucose monitoring in March 2024).
Technological Innovation in Safety Lancets: Companies are continually introducing safer, user-friendly lancets to reduce needle-stick injuries and infection risk, such as BD’s Ultra-Fine Safety line which saw a substantial market release in early 2024.
Key Trends
Adoption of Home-Based Testing: More users are shifting towards home healthcare and self-monitoring, driven by telehealth and remote patient monitoring tools, such as Roche Diagnostics collaborating with digital health firms in June 2024.
Increased Focus on Needle-Free and Painless Blood Collection: Players like Ypsomed AG and Medline are introducing minimally invasive or alternative technologies that reduce user discomfort, with several product lines rolled out in Q2 2024.
Market Insights & Segmentation
Type (Personal, Safety, Specialty, Disposable, Reusable, Others),
Application (Glucose Testing, Hemoglobin Testing, Coagulation Testing, Cholesterol Testing, Other Applications),
Distribution Channels (Hospitals, Clinics, Ambulatory Surgical Centers, Retail Pharmacies, Online Pharmacies, Others),
Technology (Manual Lancets, Automatic Lancets, Pressure Activated Lancets, Vacuum Lancets, Laser Lancets, Others),
Organization Size (Small, Medium, Large)
Key Market Companies
Abbott Laboratories, Roche Diagnostics, Becton Dickenson , Terumo Medical Corporation, Owen Mumford Ltd, ARKRAY Inc., Trividia Health Inc., Medline Industries LP, Cardinal Health Inc., Sarstedt Inc., Greiner Bio-One International GmbH, Ypsomed AG, Feather Safety Razor Co. Ltd., Nipro Corporation, HTL-Strefa S.A.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/d4-MDqGY
๐๐๐ญ๐๐ข๐ฅ๐๐ ๐๐- https://lnkd.in/dSg_gXik
The North America lancets market is set on an upward trajectory, with total revenues expected to grow from $710 Million in 2020 to an estimated $1,360 Million by 2035. This robust expansion is propelled by a surge in at-home testing, increasing prevalence of chronic illnesses such as diabetes, and innovation in minimally invasive lancet devices. Notable growth is observed in periods post-2025 due to accelerated adoption of advanced safety lancets and digital health integration. Hospitals and clinics remain major contributors, complemented by rapidly expanding sales through online channels. Year-over-year growth momentum is likely to be sustained by regulatory reforms, improved healthcare infrastructure, and ongoing product development.
Key Drivers
Rising Incidence of Diabetes: The growing number of diabetics in North America, with an estimated 37 million adults in the US alone, significantly pushes lancet demand for self-monitoring and professional diagnostics (Abbott Laboratories launched new lancet devices for continuous glucose monitoring in March 2024).
Technological Innovation in Safety Lancets: Companies are continually introducing safer, user-friendly lancets to reduce needle-stick injuries and infection risk, such as BD’s Ultra-Fine Safety line which saw a substantial market release in early 2024.
Key Trends
Adoption of Home-Based Testing: More users are shifting towards home healthcare and self-monitoring, driven by telehealth and remote patient monitoring tools, such as Roche Diagnostics collaborating with digital health firms in June 2024.
Increased Focus on Needle-Free and Painless Blood Collection: Players like Ypsomed AG and Medline are introducing minimally invasive or alternative technologies that reduce user discomfort, with several product lines rolled out in Q2 2024.
Market Insights & Segmentation
Type (Personal, Safety, Specialty, Disposable, Reusable, Others),
Application (Glucose Testing, Hemoglobin Testing, Coagulation Testing, Cholesterol Testing, Other Applications),
Distribution Channels (Hospitals, Clinics, Ambulatory Surgical Centers, Retail Pharmacies, Online Pharmacies, Others),
Technology (Manual Lancets, Automatic Lancets, Pressure Activated Lancets, Vacuum Lancets, Laser Lancets, Others),
Organization Size (Small, Medium, Large)
Key Market Companies
Abbott Laboratories, Roche Diagnostics, Becton Dickenson , Terumo Medical Corporation, Owen Mumford Ltd, ARKRAY Inc., Trividia Health Inc., Medline Industries LP, Cardinal Health Inc., Sarstedt Inc., Greiner Bio-One International GmbH, Ypsomed AG, Feather Safety Razor Co. Ltd., Nipro Corporation, HTL-Strefa S.A.
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ- https://lnkd.in/d4-MDqGY
339 Views
